Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




GenVec’s TNFerade Nears NDA Status (NASDAQ:GNVC)

Michael Vlaicu (September 9th, 2009) Writes:

GenVec, Inc.

(Public, NASDAQ:GNVC)

StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus, and Herpes Simplex Virus Type 2 (HSV-2). Surrounded by cash infusions through grants, mutual and institutional investors, multi-purpose products with billion dollar market potential, and an already flowing revenue stream – GenVec is one company you shouldn’t pass by.

About

Genvec

...
Tags for this Post:
adenovector delivery, adenovector delivery technology, adenovector technology, adenovector vaccine candidate, adenovirus, Agricultural Research Service, Allergy, America, Analyst, and Lead Investment Analyst, antibodies, Antigenics Inc., Apple Inc, Associate Professor, balance disorders, bank of america corp, Barclays, Biotechnology, California, cancer, Cancer Research, Cancers, care for patients with balance disorders, ceo, Chemotherapy, clinical disease, Dendreon Corporation;, director, Douglas J. Swirsky, esophageal cancer, Executive Vice President, Executive Vice President of Research and Development, Fda, fibrosis;, Food Supply, foot-and-mouth disease, founder, Gaithersburg;, gene expression, gene therapy, GenVec Inc., Head And Neck Cancer, hearing loss;, HIV, Infectious Diseases, Laszlo Zsak, lead therapeutic product candidate, locally advanced pancreatic cancer, Major, Malaria, manager, Marvin Grubman, Maryland, meat products, Michael Vlaicu;, multi-purpose products, National Institute of Allergy, National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Naval Medical Research Center, necrosis, Oncologix Inc., Pancreatic Cancer, parasitic disease, Patrick Swazy, Paul H. Fischer, Pfizer Inc, Ph.D., Pharmaceutical, Plum Island Animal Disease Center, president and chief executive officer, Professor of Human Oncology, Q1, radiation, rectal cancer, Researchers of the Livestock Sciences, Reuters, Royce Micro, SAIC-Frederick Inc., San Francisco, second-generation vaccine candidate, Spartan Micro, stage biopharmaceutical;, Steve Jobs, Stocks to Watch, targeted radiation therapy, therapy for locally advanced pancreatic cancer, TherAtoh, TNFerade;, TNFerade™;, transcriptional start site, treatment of inoperable, treatment of locally advanced pancreatic cancer;, treatment of pancreatic cancer, treatment of various cancers;, tumor, tumors, U.S. Department of Agriculture, U.S. Food and Drug Administration, United Kingdom, United States, University of California at San Francisco, University of California Irvine Comprehensive Digestive Disease Center, University of Denver, University Of Wisconsin, USD, USDA, vaccine candidate, Vaccine Research Center, Vaccine Research Center/National Institute, Vaccines, Vice President and Chief Financial Officer, Vice President of Research and Development, Wisconsin, Yahoo, yale, Yale University School of Medicine

PWRM, Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Dr. Stock Pick (September 2nd, 2009) Writes:

PWRM, Power 3 Medical Products Inc, PWRM.OB

drstock

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Files for 3 Patents on Blood Test

for Diagnosis of Early Stage Breast Cancer

signup3m

 

Wednesday September 2nd, 2009

************************************************************** Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced recently that the company made significant advances in the technology for their BC-SeraPro™ serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.

“Roughly 200,000 women in the US and 1.2

...

Three Valuable Patents, Potential FDA Filing (OTC:PWRM)

Michael Vlaicu (September 1st, 2009) Writes:

Power3 Medical Products, Inc.

(Public, OTC:PWRM)

The following company analysis has been contributed by a StocksHaven Investments affiliate and member, Michael Sklar. He has been studying the markets for several years now with a focus in undiscovered Bio-Pharm companies.

About

Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. In the area of neurodegenerative diseases and breast cancer, Power3 has completed research and clinical validation studies involving over 1,500 patient samples. Power3 uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company

...
Tags for this Post:
actual disease, Alan B. Hollingsworth, ALS, Alzheimer, amyotrophic lateral sclerosis, antibodies, Arizona, author, Banner Sun Health Research Institute, BC-SeraPro, Breast Cancer, cancer, Cancers, ceo, China, collector, diagnostic tests, Director of Breast MRI, ductal carcinoma in situ, Fda, Gemologist, Helen R. Park;, Ira L. Goldknopf, leukemia, Lung Cancer, Marwan Sabbagh, Maryland, Medical Director, member, Mercy Cancer, Mercy Cancer Resource Center, Mercy Women’s Center, Michael Sklar, Michael Vlaicu;, Mri, neurodegenerative disease;, neurodegenerative diseases, neurological disorders, NuroPro® AD, Oklahoma LLC, Ph.D., pharmaceutical and diagnostic, potential medical applications, Power3 Medical Products Inc.;, Power3;, President and Chief Scientific Officer, proteomics, Stocks to Watch, StocksHaven Investments;, Sun City, the Medical Director of Breast MRI, treatment of breast cancer, tumors, U.S. Food and Drug Administration, United States, USD

PWRM, Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Dr. Stock Pick (September 1st, 2009) Writes:

PWRM, Power 3 Medical Products Inc, PWRM.OB

drstock

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Files for 3 Patents on Blood Test

for Diagnosis of Early Stage Breast Cancer

signup3m

 

Tuesday September 1st, 2009

************************************************************** Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced recently that the company made significant advances in the technology for their BC-SeraPro™ serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.

“Roughly 200,000 women in the US and 1.2 million

...

PWRM, Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Dr. Stock Pick (August 31st, 2009) Writes:

PWRM, Power 3 Medical Products Inc, PWRM.OB

drstock

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Files for 3 Patents on Blood Test

for Diagnosis of Early Stage Breast Cancer

signup3m

 

Monday August 31, 2009

************************************************************** Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced recently that the company made significant advances in the technology for their BC-SeraPro™ serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.

“Roughly 200,000 women in the US and 1.2 million women

...

PWRM, Hot Stock Alert! Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Dr. Stock Pick (August 25th, 2009) Writes:

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com HOT Stock Alert!

drstock

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Files for 3 Patents on Blood Test

for Diagnosis of Early Stage Breast Cancer

signup3m

 

Tuesday August 25, 2009

************************************************************** Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Woodlands, TX, - Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that the company made significant advances in the technology for their BC-SeraPro™ serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.

“Roughly 200,000 women in

...

PWRM, Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Dr. Stock Pick (August 24th, 2009) Writes:

PWRM, Power 3 Medical Products Inc, PWRM.OB

drstock

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Files for 3 Patents on Blood Test

for Diagnosis of Early Stage Breast Cancer

signup3m

 

Monday August 24, 2009

************************************************************** Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Woodlands, TX, - Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that the company made significant advances in the technology for their BC-SeraPro™ serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.

“Roughly 200,000 women in the US and 1.2

...

PWRM Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Dr. Stock Pick (August 21st, 2009) Writes:

PWRM, Power 3 Medical Products Inc, PWRM.OB

drstock

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Files for 3 Patents on Blood Test

for Diagnosis of Early Stage Breast Cancer

signup3m

 

Friday August 21, 2009

************************************************************** Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Woodlands, TX, - Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that the company made significant advances in the technology for their BC-SeraPro™ serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.

“Roughly 200,000 women in the US and 1.2

...

PWRM Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Dr. Stock Pick (August 20th, 2009) Writes:

PWRM, Power 3 Medical Products Inc, PWRM.OB

drstock

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Files for 3 Patents on Blood Test

for Diagnosis of Early Stage Breast Cancer

signup3m

 

Thursday August 20, 2009

************************************************************** Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Woodlands, TX, - Aug 20, 2009 - Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced today that the company made significant advances in the technology for their BC-SeraPro™ serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.

“Roughly 200,000 women in the

...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.